<DOC>
	<DOC>NCT02392702</DOC>
	<brief_summary>This two-part study will assess, in healthy volunteers, under both fasted and fed conditions, and in a sequential manner, the safety, tolerability and pharmacokinetics (PK) profile of single doses of C-10355 and C-10358 and single ascending doses of the selected compound compared to a single dose of Kalydeco®.</brief_summary>
	<brief_title>Study to Evaluate Safety, Tolerability and PK of C-10355 and C-10358 in Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy adults between 18 and 50 years of age, inclusive Body weight ≥ 50 kg and BMI within the range of 18 to 30 kg/m2, inclusive, at screening History of clinically significant central nervous system (eg, seizures), cardiac, pulmonary, metabolic, renal (including nephrolithiasis), hepatic, including history of Gilbert's syndrome or gastrointestinal (GI) conditions PR interval ≥ 220 msec or QRS duration ≥ 120 msec or QTcF interval &gt; 450 msec obtained at screening visit or prior to the first dose of study drug Liver function tests greater than the upper limit of normal. Positive blood screen for human immunodeficiency virus (HIV antibody), hepatitis B virus surface antigen, or hepatitis C virus antibody at screening Urinalysis positive for greater than trace blood, protein or glucose A positive screen for alcohol, drugs of abuse, or tobacco use. Inability to comply with food and beverage restrictions during study participation. Donation or blood collection or acute loss of blood prior to screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Subjects</keyword>
	<keyword>Safety/Efficacy Study</keyword>
	<keyword>Randomized</keyword>
	<keyword>Open Label</keyword>
</DOC>